Table 5.
Patient data and tumor characteristics, twelve patients treated with T or T + A implants diagnosed with invasive breast cancer March 2008–March 2018 within 240 days of receiving therapy
| Patient | Age at 1st TT Y | Age at IBC dx. Y | BMI 1st TT | Meno Status 1st TT | Prior E use | Detection | N days Last insert prior to dx | IBC (Stage) Type | Receptor status | Continued TT post dx |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 46.2 | 49.3 | 19.2 | TAH FSH 4.6 | Y | Mammo | 206 d | T1b, N0 (1) Gd 2 IDC | ER+, PR+ Her 2 - | |
| 2 | 55.0 | 59.2 | 33.3 | Post | Y | Palpable | 123 d | T3, N2 (3) Gd 3 IDC | ER-, PR-Her 2 - | |
| 3 | 50.0 | 52.9 | 19.2 | Pre | OCP Current | Mammo | 34 d | T1c, N0 (1) Gd 1 IDC | ER+, PR+ Her 2 - | T + AI x 5y T alone |
| 4 | 67.6 | 70.2 | 24.7 | TAH BSO | Y | Mammo | 151 d | T1b, N0 (1) Gd 1 IDC | ER+, PR+ Her 2 – | |
| 5 | 44.9 | 48.5 | 21.5 | TAH | N | Mammo | 48 da | T1c, N0 (1) Gd 1, IDC | ER+, PR- Her 2 - | |
| 6 | 48.9 | 55.5 | 24.4 | TAH | Y | Mammo | 146 d | T1b, N1a (2) Gd 2 ILC | ER+, PR- Her 2 - | |
| 7 | 56.2 | 60.6 | 28.8 | TAH BSO | Y | Mammo | 51 d | T1 N0 (1) Gd 2 IDC | ER+, PR+ Her 2 - | |
| 8 | 50.0 | 55.2 | 28.7 | Post | N | Mammo | 54 d | T1a N0 (1) 1.2 mm IDC | ER-, PR+ Her 2 - | T alone |
| 9 | 58.0 | 61.5 | 39.3 | TAH BSO | N | Palpable | 50 d | T2 N1 (2) Gd 3 IDC | ER+ PR+ Her 2 - | T + AI Note: tested BRCA 2 pos. |
| 10 | 39.7 | 43.4 | 23.2 | Pre | N | Palpable | 15 d | T1c N0 (1) Gd 2 IDC | ER+ PR+ Her 2- | |
| 11 | 44.0 | 51.0 | 23.5 | Pre | N | Mammo | 92 d | Clinical T2 N0 (2A) Gd 3 IDC | ER+ PR+ Her 2 + | T + AI |
aPatient was diagnosed 48 d after a single pellet insertion following a 23-month lapse in therapy
Abbr: TT testosterone therapy, IBC (invasive breast cancer), Dx. (diagnosis), BMI (Body mass index), E2 (estradiol), OCP (Oral Contraceptive Pill), IDC (Infiltrating ductal carcinoma), ILC (infiltrating lobular carcinoma), T (tumor size), a (< 0.5 cm), b (> 0.5, < 1 cm), c (> 1, < 2 cm), T2 (20mm–50mm), T3 (> 50 mm), N (node status); N0 (no nodes positive), N1a (Single node < 5 mm), N2 (4–9 nodes positive), Gd (tumor grade: 1 low grade, 2 intermediate grade, 3 high grade), ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor 2), T (testosterone implant), T + AI (testosterone combined with an aromatase inhibitor implant), Mammo (mammography)